Quantcast

Latest Adenocarcinoma Stories

2011-06-30 19:17:03

UNC completes miRNA and array analysis As part of The Cancer Genome Atlas (TCGA) projectIcon indicating that a link will open an external site., UNC Lineberger researchers have contributed to the most comprehensive and integrated view of cancer genes for any cancer type produced to date. The UNC team, which includes Charles Perou, PhD, professor of pathology and laboratory medicine and genetics, Neil Hayes, MD, associate professor of hematology/oncology, and Katie Hoadley, PhD, Research...

2011-06-30 07:04:44

(Ivanhoe Newswire) "“ A key for early diagnosis of cancer and personalized medicine is the order of genetic aberrations - deviations or irregularity - in individual cancers. Now, scientists have begun to reveal the order of mutations that lead to cancer. "We know that each cancer is a collection of genetic malfunctions," Raymond Cho, Ph.D., assistant clinical professor in the department of dermatology at the University of California, San Francisco, was quoted as saying. "We now know it...

2011-06-28 08:00:00

EXTON, Pa., June 28, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC). The study will evaluate farletuzumab, a monoclonal antibody that specifically binds to folate receptor-alpha (FRA), with the physician's choice of one of three standard platinum-containing doublets that are approved and...

2011-06-05 08:00:00

INDIANAPOLIS, June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC). "Continuation maintenance"...

2011-05-20 17:14:00

MANHATTAN BEACH, Calif., May 20, 2011 /PRNewswire/ -- The Pfizer drug Sutent® (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA). Sutent® is the second targeted drug to be approved this month for the treatment of pancreatic neuroendocrine tumors, which make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less...

2011-05-16 15:11:34

A simple, minimally-invasive technique using cells from the interior of the nose could help clinicians detect lung cancer in its earliest "“ and most treatable "“ stages, according to a study conducted by researchers in Boston. The study will be presented at the ATS 2011 International Conference. "Our data suggests that evaluating gene expression changes in nasal cells found in the interior surface of the nose may serve as a non-invasive approach for the early detection of lung...

2011-05-06 08:55:00

MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma. (Logo:...

2011-04-25 16:02:11

A new study reports that multipolar electrocoagulation in combination with acid suppression is a safe and effective method to ablate nondysplastic Barrett's esophagus over the long term. No adenocarcinoma (cancer) or high-grade dysplasia of the esophagus developed in any of the study patients. This is the largest published series and longest follow-up of patients with nondysplastic Barrett's esophagus who underwent ablation therapy with multipolar electrocoagulation. The study appears in the...

2011-03-16 08:20:01

(Ivanhoe Newswire) -- Heavy drinking is not associated with one of the two most common types of gullet (oesophageal) cancer, according to this study. Gullet cancer is the sixth leading cause of cancer death worldwide and occurs as one of two main types: squamous cell carcinoma or adenocarcinoma. But while rates of gullet adenocarcinoma have soared in many Western countries over the past three decades, those of squamous cell carcinoma have been falling. The squamous cell variety is strongly...

2011-03-15 14:34:19

Alcohol intake and risk of esophageal adenocarcinoma: A pooled analysis from the BEACON Consortium Heavy drinking is not associated with one of the two most common types of gullet (oesophageal) cancer, suggests research published online in Gut. Gullet cancer is the sixth leading cause of cancer death worldwide and occurs as one of two main types: squamous cell carcinoma or adenocarcinoma. But while rates of gullet adenocarcinoma have soared in many Western countries over the past three...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related